Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged ≥12 years from the date of informed consent~* Confirmed diagnosis of CF at screening~* Confirmed EPI by historical (within past 12 months) CFA \<70% without use of PERTs or current fecal elastase \<50 µg/g stool at screening~* Currently receiving PERT with a commercially available pancreatic enzyme~* Currently on stable treatment with proton pump inhibitors or H2 receptor antagonists~* Clinically stable condition without evidence of acute respiratory disease or any other acute condition~Exclusion Criteria:~* History of fibrosing colonopathy~* History of significant bowel resection, in the opinion of the investigator, or solid organ transplant~* History of being refractory to pancreatic enzyme replacement~* Current diagnosis or history of distal intestinal obstruction syndrome~* Current diagnosis of small intestinal bacterial overgrowth, ileus or acute abdomen~* A body mass index percentile \<10%

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Burlulipase (Type: EXPERIMENTAL): Burlulipase orally, per meal
- Placebo (Caramel in sterile water) (Type: PLACEBO_COMPARATOR): Placebo orally, per meal

Based on this trial design, predict the completion outcome and termination type (if applicable).